Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Deal Watch: Astellas/Cytokinetics Extend Partnership, Make Progress On SMA Candidate

Executive Summary

The two firms hope improvement in the six-minute walk test might be accepted by the US FDA as registrational endpoint for reldesemtiv in spinal muscular atrophy. Blackstone acquires Clarus, while Merck licenses TriNKETs from Dragonfly.

Advertisement

Related Content

J&J Bets Big On Arrowhead’s Early Promise In Hepatitis B
Aduro Says End Of Janssen Collaborations “Not A Lethal Blow”
Boston Bags Assets From GSK and Novartis
Momenta Is Exiting Biosimilars; Is That A Bellwether For Biosimilar Sentiment?
EU Approval Set For Three New Orphans And Lilly’s Emgality; Exondys Appeal Fails
Galera Raises $150m To Take Lead Drug From Phase III To NDA Submission
Deal Watch: LEO Pharma Expands Market Reach Through Bayer Dermatology Deal
Cystic Fibrosis: NovaBiotics Advances Old Dog With New Tricks
Sanofi Finalizes Zentiva Sale With Focus Back On Turnaround
With Phase III Failure, Cytokinetics Shelves Tirasemtiv, Pivots To ALS Backup

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC123960

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel